Print ISSN:-2394-2789
Online ISSN:-2394-2797
CODEN : IJPCN9
Review Article
Author Details :
Volume : 9, Issue : 3, Year : 2022
Article Page : 114-118
https://doi.org/10.18231/j.ijpca.2022.020
Abstract
Drug resistance in tuberculosis has been shown to result from spontaneous mutation in several chromosomal genes of M.Tuberculosis. Mutation may reduce the medications' capacity to bind to the target genes. In many patients polydrug resistance, multidrug resistance, rifampicin resistance (RR) and extensive drug resistance (XDR) were seen. The diagnosis of drug-resistant TB in HIV-ith mono- or positive persons is more difficult and may be confused with other pulmonary or systemic infections. Management of patients wpoly-resistant TB will be done with standard first line chemotherapy. Treatment of latent infection for people suffering from multidrug resistant bacilli is problematic because the only cure by isoniazid and rifampicin. In the recent cases of severe hepatotoxicity associated with preventive treatment comprising either pyrazinamide and rifampicin or pyrazinamide and fluoroquinolone. The use of dilatory fluoroquinolones, such as moxifloxacin, remarkable improved treatment outcomes of XDR-TB.
Keywords: Tuberculosis, Drugresistance TB, Mechanism of drug resistance
How to cite : Gohil C J, Parmar K C, Patel P R, Gohil J J, Mechanism and management of antibiotic drug resistance tuberculosis. Int J Pharm Chem Anal 2022;9(3):114-118
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.